Methods of treating renal disease or treating at least one of muscle wasting, low muscle strength, or low physical function in a subject having renal disease by administering at least one tetrahydrocyclopenta[b]indole compound are disclosed. Also disclosed are methods of treating symptoms as a result of secondary hypogonadism induced by renal replacement therapy or kidney failure in a subject having renal disease by administering at least one tetrahydrocyclopenta[b]indole compound. The methods of treatment disclosed herein also include co-administration of the tetrahydrocyclopenta[b]indole compound with a second composition

The current invention is based on the determination that a S1P receptor modulator compound of formula (I):

##STR00001##

decreases the heart rate of a subject to which it is administered by about 5 beats/min or less daily, or about 4 beats/min or less daily, or about 3 beats/min or less daily, or about 2 beats/min or less daily, wherein the S1P receptor modulator is administered at an initial daily dosage which is substantially the same as the standard daily therapeutic dosage.

The present invention provides a method of treating a respiratory illness in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound comprising a reaction product of a reaction mixture comprising: a) N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide or a derivative thereof; and b) dimethyl sulfoxide. Also provided are methods of alleviating opioid addiction while suppressing withdrawal symptoms and alleviating inflammation and visceral pain with minimal risk of addiction in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the compound described above.

Disclosed are methods for mitigating one or more debilitating symptoms of a mTBI for a patient diagnosed with sustained mTBI. These methods comprise administering an effective amount of ghrelin or a variant thereof over multiple consecutive days after the diagnosis of a sustained mTBI.

The present invention relates to an adhesive composition comprising a polyvinyl alcohol and a water-soluble polyphenol compound, to an adhesive comprising the same, and to a manufacturing method therefor and, more specifically, to an adhesive composition, which has little toxicity, can adhere even without a curing process unlike a conventional adhesive, enables the manufacturing of a gel by hydrogen binding characteristics between the polyvinyl alcohol compound and the water-soluble polyphenol compound, and retains adhesive properties in water.

Natural honey and a surfactant are combined to achieve a novel wound treatment composition. The honey is chosen for its medicinal properties, and the surfactant is used for biofilm removal to enhance the effectiveness of the honey. In preferred embodiments, the honey is a tropical honey currently sourced from Mexico. The surfactant is mixed with water, then the aqueous mixture is combined with the honey. In accordance with a preferred embodiment, a surfactant powder is mixed with water at a ratio of 10% powder to water, then that mixture is combined with honey at a ratio greater than 50:50, more preferably at a ratio of 90:10. The currently preferred surfactant is Poloxamer 188. The product may be applied directly to a wound or applied to wound dressings including, without limitation, gauze, gauze rolls, hydrocolloids, and calcium alginate dressings.

Presented herein, in certain aspects, are cell-free therapeutic composition derived from human amniotic fluid (HAF) and uses thereof for the prevention and treatment of selected diseases and disorders.

The invention relates to a composition for the topical treatment and care of psoriatic skin. It consists exclusively of natural substances and comprises at the most peanut oil, olive oil, castor oil, avocado oil, rose oil, rose hydrolate, lanolin and phytosterol in the form of a mixture of at least peanut oil, olive oil, castor oil and lanolin.

Disclosed is an iontophoresis-based patch type medicine absorption device for allowing a medicine for medical treatment or a functional substance for skin care to be effectively absorbed into a user's skin by causing iontophoresis on the user's skin through a conductive patch. The iontophoresis-based patch type medicine absorption device for allowing the medicine for medical treatment or the functional substance for the skin care to be absorbed into the user's skin by the iontophoresis includes a medicine absorption device body that generates power to cause the iontophoresis. The medicine absorption device body includes a power circuit that is provided in an interior space of a body and that includes a power unit that generates the power for the iontophoresis and one or more electrodes to which the power is applied, and a bridge that is provided so as to be combinable with the body and that receives the power through the one or more electrodes. The bridge includes a bridge body provided so as to be combinable with the body and a plurality of bridge legs arranged along a circumferential direction of the bridge body and formed of a conductive material.

The present invention provides for methods of obtaining an extract of Cannabis plant material as well as subsequent processing of the extract to provide a concentrate of Cannabis. The present invention also provides for pharmaceutical dosage forms (e.g., oral thin films and transdermal patches) that include the concentrate (or extract) of Cannabis, as well as methods of medical treatment that include administering the pharmaceutical dosage forms.